Daniel S. Raccuia, PharmD candidate 2016

home / authors / daniel-s-raccuia-pharmd-candidate-2016

Daniel S. Raccuia is a 2016 PharmD candidate at University of Connecticut School of Pharmacy, Storrs, Conn.

Articles

Site Logo

FDA approves rolapitant to prevent chemotherapy-induced nausea and vomiting

June 10th 2016

Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.

© 2024 MJH Life Sciences

All rights reserved.